Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Capital Expenditures (2017 - 2022)

Historic Capital Expenditures for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to $45000.0.

  • Iterum Therapeutics' Capital Expenditures rose 24615.38% to $45000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $65000.0, marking a year-over-year increase of 17083.33%. This contributed to the annual value of $2000.0 for FY2024, which is 8461.54% down from last year.
  • According to the latest figures from Q4 2022, Iterum Therapeutics' Capital Expenditures is $45000.0, which was up 24615.38% from $7000.0 recorded in Q3 2022.
  • Iterum Therapeutics' Capital Expenditures' 5-year high stood at $45000.0 during Q4 2022, with a 5-year trough of $2000.0 in Q4 2019.
  • Moreover, its 5-year median value for Capital Expenditures was $13000.0 (2021), whereas its average is $17090.9.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 9047.62% in 2019, then surged by 24615.38% in 2022.
  • Quarter analysis of 5 years shows Iterum Therapeutics' Capital Expenditures stood at $21000.0 in 2018, then tumbled by 90.48% to $2000.0 in 2019, then surged by 350.0% to $9000.0 in 2020, then skyrocketed by 44.44% to $13000.0 in 2021, then soared by 246.15% to $45000.0 in 2022.
  • Its Capital Expenditures was $45000.0 in Q4 2022, compared to $7000.0 in Q3 2022 and $13000.0 in Q4 2021.